ArticleThe Journal of international medical research2023
Identifying the optimal cutoff point of Ki-67 in breast cancer: a single-center experience.
Article in The Journal of international medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Ki67 Gene Expression is Associated with Immune Cell Infiltration and Neoadjuvant Chemotherapy Response in ER+/HER2- Breast Cancer.Annals of surgical oncology · 2026Article
- AI software as a third reader in breast cancer screening-a prospective diagnostic observational study.European radiology · 2026Observational
- Optimization of Ki67 digital image analysis in breast cancer by automated tumor area identification.Virchows Archiv : an international journal of pathology · 2026Article
- Splenic Rupture Due to Metastasis of Breast Cancer: A Report of a Rare Case and Focused Literature Review.Cureus · 2026Article
- Tumors >2 cm in node-negative, HER2-positive breast cancer: comparing neoadjuvant dual-targeted versus adjuvant single-targeted treatment pathways in real-world practice.Therapeutic advances in medical oncology · 2026Article
- Comment on Hasan et al. Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma.Clinics and practice · 2025Article
- Decoding Breast Cancer: Emerging Molecular Biomarkers and Novel Therapeutic Targets for Precision Medicine.International journal of molecular sciences · 2025Review
- CCR5 expression and conformational stability as potential cooperative modulators of immune phenotypes and therapy response in breast cancer.Discover oncology · 2025Article
- Automated quantification of Ki-67 expression in breast cancer from H&E-stained slides using a transformer-based regression model.Breast cancer research : BCR · 2025Article
- Establishment and molecular characterization of novel luminal A and luminal B canine mammary cancer cell lines for comparative oncology.Veterinary world · 2025Article
- Current advances in cancer immunohistochemistry: a new perspective for the Ki-67 biomarker.Ecancermedicalscience · 2025Review
- Astragalus polysaccharide enhances the therapeutic efficacy of cisplatin in triple-negative breast cancer through multiple mechanisms.Oncology research · 2025Article
- Tumour budding in invasive ductal breast carcinomas: correlation with clinicopathological prognostic parameters and hormone receptor status.Pathology oncology research : POR · 2025Article
- CAMSAP3 Suppresses Breast Cancer Metastasis and Serves as an Independent Prognostic Marker.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveKi-67 is associated with breast cancer subtypes, but the optimal cutoff point of Ki-67 has not been established in our center. We evaluated the cutoff point of Ki-67 in breast cancer and analyzed the associations among Ki-67, clinicopathological features, and prognosis.
methodsThe clinicopathological data and prognostic information of patients with breast cancer treated in our center were retrospectively collected, and the optimal cutoff point of Ki-67 was determined by univariate and multivariate survival risk analyses. The cutoff point was used to group the patients, and the differences in the clinicopathological features and prognosis were analyzed between the two groups.
resultsIn total, 609 patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative primary breast cancer were enrolled. The mean Ki-67 value was 22.3% ± 15.4%, the median was 20%, and a cutoff point of 30% was an independent factor influencing recurrence-free survival. When 30% was used as the cutoff point, patients with a Ki-67 value of ≤30% had a better prognosis and lower tumor malignancy.
conclusionThe optimal cutoff point of Ki-67 in breast cancer in our center is 30%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.